Ocugen Inc. (OCGN): Price and Financial Metrics
OCGN Price/Volume Stats
Current price | $0.83 | 52-week high | $1.98 |
Prev. close | $0.81 | 52-week low | $0.52 |
Day low | $0.79 | Volume | 4,959,500 |
Day high | $0.85 | Avg. volume | 3,973,720 |
50-day MA | $0.68 | Dividend yield | N/A |
200-day MA | $0.87 | Market Cap | 242.39M |
OCGN Stock Price Chart Interactive Chart >
Ocugen Inc. (OCGN) Company Bio
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
OCGN Price Returns
1-mo | 22.58% |
3-mo | 18.54% |
6-mo | -8.53% |
1-year | -55.14% |
3-year | -62.78% |
5-year | 166.03% |
YTD | 3.11% |
2024 | 40.00% |
2023 | -55.77% |
2022 | -71.43% |
2021 | 148.63% |
2020 | 251.92% |
Loading social stream, please wait...